Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)

CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
October 16, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine

Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE...
October 02, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018

Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study of VBI-1501Oral presentation at IDWeek 2018 on Saturday, October 6th, 2018, at 11:10 AM PDT ...
September 27, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present at the Ladenburg Thalmann 2018 Healthcare Conference

CAMBRIDGE, Mass., Sept. 27, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
September 26, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards

CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
September 25, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients

Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationIntermediate-dose study arm: enrollment complete Initial immunologic data from low...
September 16, 2018 01:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Responds to Unfounded Allegations in Globes Article

CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12,...
September 16, 2018 01:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Responds to Unfounded Allegations in Globes Article

CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12,...
August 28, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
August 15, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head of Business Development

CAMBRIDGE, Mass., Aug. 15, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company, today announced the appointment of Christopher McNulty as...